Pfizer Limited has entered into an exclusive 5-year marketing and distribution agreement with Cipla Limited for four pharmaceutical brands in the Indian market. The partnership, disclosed through regulatory filing under Regulation 30 of SEBI listing requirements, grants Cipla sole rights to market and distribute key Pfizer brands across India.

Exclusive Partnership Details

Under the agreement, Cipla now has exclusive rights to market, distribute and sell four specific Pfizer brands. The partnership covers established therapeutic products across multiple categories, with Pfizer continuing to manufacture, source and supply these medicines to Cipla for the Indian market.

Brand Portfolio Coverage

The agreement encompasses four key pharmaceutical brands spanning different therapeutic areas. These products represent established market presence in their respective categories, providing Cipla with enhanced portfolio diversification.

Workforce Impact and Financial Implications

The partnership will result in certain reduction in Pfizer Limited's field force as part of the transition to Cipla's distribution network. Pfizer has committed to supporting impacted colleagues for their career transition during this organizational change.

Strategic Market Implications

Meenakshi Nevatia, Country President of Pfizer India, emphasized that expanding medicine reach for patients remains paramount, highlighting the partnership's potential to serve millions of patients across India effectively. The collaboration combines Pfizer's legacy of quality and innovation with Cipla's extensive distribution network.

Achin Gupta, Global Chief Operating Officer at Cipla, noted that meaningful partnerships help make strong brands even stronger. The association aligns with Cipla's continued focus on building formidable presence across key therapy areas while enhancing access to high-quality treatments guided by their purpose of "Caring for Life."

Commercial Framework

The agreement involves no upfront consideration between the parties, with other commercial terms agreed upon privately. This marks the first partnership between Pfizer and Cipla in India, combining Pfizer's well-established portfolio with Cipla's deep market penetration capabilities across the country's pharmaceutical distribution network.

360ONE WAM Limited has allotted 2,12,637 equity shares of face value Re. 1 each to employees upon exercise of stock options under the company's Employee Stock Options Scheme, as announced on December 18, 2025. The allotment was approved by the Nomination and Remuneration Committee of the Board of Directors through a circular resolution passed on the same date.

Share Allotment Details

The equity shares were allotted under the company's employee stock option schemes, reflecting the organization's commitment to employee participation in equity ownership. The allotment represents a significant distribution of shares to eligible employees who exercised their stock options.

Impact on Share Capital

Following this allotment, the company's issued, subscribed and paid-up share capital has increased substantially. The share capital structure demonstrates the company's growth in employee participation through equity ownership programs.

Regulatory Compliance

The company has informed both BSE Limited and National Stock Exchange of India Limited about this development in compliance with regulatory requirements under Regulation 30. The communication was signed by Rohit Bhase, Company Secretary (ACS: 21409), ensuring proper disclosure to all relevant stakeholders and maintaining transparency in corporate governance practices.